Regulation of the p53 tumor suppressor protein occurs to a large extent through control of protein stability, and the MDM2 protein has been shown to play a key role in targeting p53 for degradation. Stress signals that activate the p53 response lead to stabilization of p53 through inhibition of MDM2 mediated degradation, and it is becoming evident that a number of mechanisms exist to abrogate this activity of MDM2. Other members of the p53 protein family may also be regulated through protein stability, although MDM2 is not responsible for the degradation of p73. Nevertheless, interactions of p63 and p73 with MDM2 or p53 have been described, suggesting that each of the p53-related proteins can play some role in regulating the activity of the others Keywords: p53; p73; p63; MDM2; E2F-1; protein stability Common themes, different players: Regulation of p53, p73 and p63
The tumor suppressor protein p53 has been studied intensively over the past decade, and it is clear that p53 activity plays an important role in preventing tumor development. p53 is a potent inhibitor of cell growth and so control of p53 activity is essential during normal growth and development. Regulation of p53 has been described at the level of transcription and translation, 1 and through allosteric regulation of p53 conformation. 2 However, by far the most attention has been directed to modulation of p53 protein stability which appears to be one of the critical mechanism by which p53 function is regulated, and the mechanisms through which p53 is degraded have been under intense scrutiny over the past few years. The recent identification of the p53 related proteins, p63 and p73, has raised the question of whether all the family members are regulated through the same mechanisms to allow for a coordinated response, or whether each protein is subject to independent regulation. This review aims to summarize the present models on how the p53 protein is degraded and how these pathways are inhibited to allow activation of a p53 response, with comparisons to our, as yet, less comprehensive understanding of how p73 and p63 activity is controlled.
Key player in the regulatory cellular concert: MDM2
The importance of regulation of p53 stability was revealed in key studies showing that DNA damage induced activation of the p53 response resulted in a rapid increase in protein level due to a significant increase in protein half-life. 3, 4 Use of protease inhibitors and cells lacking components of the proteasome indicated that the principal regulator of p53 stability is the ubiquitin-dependent proteolytic machinery, 5, 6 although a role for calpain has also been suggested by several studies. 7 ± 9 Although elegant studies showed that a viral protein, the human papillomavirus E6 protein, could efficiently target p53 for degradation, 10 a cellular factor that can regulate the rapid degradation of p53 in normal cells remained elusive until the MDM2-protein was identified as a regulator of p53 levels through proteasome-dependent degradation.
11 ± 13 MDM2 has long been known as the product of a p53 inducible gene, 14, 15 although there is no evidence that MDM2 mediates any of the p53-functions such as cell-cycle arrest or apoptosis. 16, 17 On the contrary, MDM2 has been shown to inhibit p53 functions by binding to the Nterminus of the p53 protein and thereby blocking the normal trans-activating function of this domain. 18 ± 21 An autoregulatory feedback loop is therefore established between p53 and MDM2, where p53 activates expression of its own negative regulator. 15 The importance of MDM2-regulation of the p53 protein is reflected in the fact that MDM2 deficient mice show a very early embryonic lethality which is entirely rescued when the p53 gene is simultaneously deleted. 22, 23 This strongly argues that a crucial function of MDM2, at least during early development, is the regulation of the growth inhibitory activities of p53. Furthermore, inhibition of MDM2 activity in normal cells also leads to elevation of p53 levels and activation of a p53 response. 24, 25 Taken together, it seems likely that the MDM2/p53 feedback loop maintains p53 at low levels in normally growing, unstressed cells. Perturbation of this regulatory loop results in stabilization of p53, and this situation is seen in tumor cells expressing mutant forms of p53 that have lost transcriptional activity. Mutations of this type not only abolish the tumor suppressive functions of p53 but also prevent p53 activation of MDM2. The consequence of this is the stabilization of p53, a characteristic often associated with mutant p53 in tumor cells.
Having established a role for MDM2 in the degradation of p53, rapid progress has been made in elucidating the mechanisms by which MDM2 functions. It has been shown that MDM2 reduces the intracellular p53 levels in a ubiquitin-proteasome mediated pathway, 11, 12 and that MDM2 itself can function as an E3 ubiquitin-ligase, mediating both p53-ubiquitination as well as its own ubiquitination in vitro. 26 ± 28 E3 ligases are required for the specificity of ubiquitin conjugation, a multi-enzyme process that leads to the covalent modification of proteins with ubiquitin, 29 and the ubiquitination of p53 and MDM2 itself requires only E1 (ubiquitin activating enzyme) and E2 (ubiquitin conjugating enzyme) in addition to MDM2. 28 This activity of MDM2 depends on the RING finger in the Cterminus of the protein and in this respect MDM2 shows similarity to other RING finger containing proteins that have intrinsic capacities to mediate ubiquitination. 30 It seems possible that these RING fingers, which vary substantially in their sequences, may be responsible for the target specificity of the E3 ligases. 28, 30 In addition to the role of MDM2 as an E3 ligase, the efficient degradation of p53 is also dependent on the nucleo-cytoplasmatic shuttling of MDM2.
31 ± 35 The importance of subcellular transport of MDM2 was demonstrated by using drugs that block nuclear export 31 ± 33 and MDM2-mutants that are deficient for nuclear export. 31, 34 Although these studies are supportive of the model in which MDM2 is responsible for moving p53 from the nucleus to the cytoplasm, where degradation occurs through cytoplasmic proteasomes, it is possible that MDM2 and p53 export from the nucleus independently. A nuclear export signal has recently been described in the oligomerization domain of p53 suggesting direct regulation of p53 export and stability depending on the oligomerization state of p53. 36 Although the details of this regulation remain to be established, overall it seems clear that p53 degradation can be regulated by control of the subcellular localization of p53 and MDM2.
Both p53 and MDM2 have been shown to bind to many other proteins, and these interactions can also influence the ability of MDM2 to target p53 for degradation. Several of these interactions result in the inhibition of degradation, and may play a role in allowing the activation of p53 (see below). By contrast, the transcriptional coactivators p300/ CBP appear to play an important role in allowing MDM2 mediated degradation of p53. p300/CBP binding to the trans-activation domain of p53 is important for the transcription function of p53 and its growth arrest and apoptotic functions.
37 ± 40 Interestingly, p300 binding has been shown to be particularly important for activation of MDM2 expression 41 and degradation of p53. In addition, p300 has been proposed to play a direct role in promoting degradation of p53 by interacting with both MDM2 and p53 through domains distinct from those important for p300 to serve as a transcriptional coactivator. 42 In this way p300 might act as a binding platform to allow assembly of the protein complexes necessary for p53 degradation.
New insights into p73-degradation p73, which shows highest homology to p53 within the core DNA-binding region, has been shown to trans-activate similar target genes as p53, although the relative efficiency of transcriptional activation can differ. 43 ± 46 Various isoforms of p73 stimulate the expression MDM2, 47 and since most studies show that MDM2 also reduces p73-dependent transcription in different in vitro reporter assays, 47 ± 49 it would appear possible that a similar feedback loop to that seen with p53 and MDM2 can exist for p73. Inhibition of p73 function by MDM2 is dependent on the interaction between the two proteins, prompting several studies to determine whether the stability of p73 is also regulated by MDM2. Like p53, the p73 alpha protein is degraded though the ubiquitindependent proteasome pathway, 46,48 but it is now clear that MDM2 does not mediate degradation of p73 alpha or beta. 47 ± 49 In contrast to its effect on the p53-protein, MDM2 stabilizes p73 alpha and beta levels, 47, 50 suggesting that MDM2 binding may protect p73 from the normal degradative mechanisms ( Figure 1 ). The basis for the resistance of p73 to MDM2 mediated degradation is not yet understood, although the observation that the extreme C-terminus of p53, a region not conserved in p73, is necessary for allowing efficient degradation in response to MDM2 51 suggests a contribution of this region.
Stabilization of p53 upon cellular stress signals
In order to perform its cellular functions of growth arrest and/or apoptosis, the basal levels of p53 must be raised quickly in response to cellular stress signals such as DNA damage, oncogene activation or hypoxia. During the last years considerable insight has been gained as to how p53 can be stabilized and activated, and how the normally efficient degradation of p53 can be inhibited. Most of these studies have focused on the elucidation of how p53 can overcome MDM2-mediated degradation, and how the feedback-loop between p53 and MDM2 can be interrupted.
It seems clear now that the MDM2-mediated degradation of p53 can be overcome through several independent mechanisms ( Figure 2) . One of the most straightforward ways to stabilize p53 would be to prevent the p53/MDM2 interaction by stress signal induced modifications of p53 or MDM2 or both. Various DNA-damaging agents which stabilize p53 have been shown to induce site-specific phosphorylation of p53 52 and many kinases, including ATM, ATR, DNA-PK, JNK and CKI, can phosphorylate the N- 53 Various studies have shown that phosphorylation of the p53-protein or p53-peptides at serine 15, serine 20, serine 37 or threonine 18 reduces the interaction between p53 and MDM2 54 ± 57 and these observations are supported by the structural requirements for p53 and MDM2 to form a complex.
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Mutant p53 with substitutions of both serines 15 and 37 to aspartic acid, mimicking phosphorylation of those two sites, is slightly resistant to complete degradation by MDM2, 59 while mutation of serine 20 to a non-phosphorylable amino acid results in enhanced sensitivity to degradation. 55 The dependence on phosphorylation of any of these sites has been difficult to prove however, and mutation of all possible phosphorylation sites in this N-terminal region of p53 does not prevent efficient stabilization in response to DNA damage.
59,60 Indeed, it is becoming evident that different patterns of phosphorylations occur in response to different stress signals, suggesting that specific phosphorylation, or combinations of phosphorylation may contribute to responses to various forms of stress. In cells, ATM and the ATM-Rad3-related protein ATR have been shown to play a role in activation of p53 following DNA double-strand breaks, but other kinases are also likely to contribute to different stress responses. 61 It seems most likely that phosphorylation of p53 can contribute to the stabilization of the protein in response to some activating signals, but that this modification is not essential for inhibition of MDM2 mediated degradation.
Another possible target for the above mentioned kinases is MDM2, which is also a phosphoprotein 18 ,62 and modifications of MDM2 might inhibit its ability to target p53 for degradation. In vitro experiments have shown that MDM2 can be phosphorylated by DNA-PK and that this phosphorylation blocks its association with p53.
63 MDM2 was found to be phosphorylated by casein kinase 2 in vitro, 64 although so far none of these results have been confirmed in vivo.
p53-stabilization by ARF
One phosphorylation-independent mechanism of p53-stabilization that has emerged during the past year involves activation of expression of the human p14ARF (mouse p19ARF) protein. The ARF protein is encoded by the INK4a-ARF locus which encodes two distinct proteins translated from alternatively spliced mRNAs: the a-transcript comprising exons 1a, 2 and 3 specifies p16INK4a, a cyclindependent kinase inhibitor 65 ± 67 and an alternative product, ARF (`alternative reading frame') encoded by exons 1b, 2 and 3.
68 ± 70 The importance of the ARF-INK4a locus is reflected in the fact that it shows genetic alterations in human cancers almost as often as the p53 locus 66,67,71,72 and that ARFdeficient mice develop tumors. 73 Furthermore, in human tumor cell lines retention of wild-type 53 often goes together with a loss of ARF expression 74 suggesting that these two proteins participate in the same tumor suppressive pathway.
The first hint that ARF might function in a pathway involving p53 came from the observations that ARF can arrest cell-cycle progression and block myc/ras transformation through a p53-dependent mechanism.
73 ± 77 ARF functions by binding directly to MDM2 in a region distinct from the p53 binding domain, and prevents degradation of p53 without inhibiting the ability of p53 and MDM2 to interact. 74 ± 77 In in vitro assays ARF can inhibit the ubiquitination function of MDM2, 26, 27 preventing both p53 ubiquitination as well as the auto-ubiquitination of MDM2 itself.
27 Although direct inhibition of MDM2's E3 ligase activity would efficiently prevent p53 degradation, recent studies have shown that ARF also has the ability to interfere with the nucleo-cytoplasmic shuttling of MDM2 that is essential for p53 degradation.
31,32,34,78 Expression of ARF leads to the relocalization of MDM2 from the nucleoplasm into the nucleolus 35,79 leaving p53 in the nucleoplasm where it is free to activate expression of the mediators of the p53. This nucleolar relocalization depends on signals in the ARF protein, and mutations of the nucleolar localization signal results in the retention of both proteins in the nucleoplasm. 78 
Role of E2F1 in the activation of p53
Activation of p53 appears to be a general response to many types of stress, including DNA-damaging events and abnormal proliferative signals. The mechanisms underlying the response to abnormal proliferation have become evident with the realization that deregulated expression of the E2F-transcription factors, which control the expression of many genes necessary for cell growth, can also induce both p53 and p73. Loss of the normal regulation of the E2F family is a very common event, found in most cancers, 80 strongly suggesting that uncontrolled expression of these transcription factors is necessary for tumor development. A failsafe mechanism to protect from such events is revealed by the ability of one family member, E2F-1, to activate apoptosis. 81 It is becoming apparent that this E2F-1 response can be carried out in a p53-dependent and a p53-independent fashion, and loss of p53 significantly diminishes the apoptotic response to deregulated E2F-1 expression (Figure 3) . Deregulation of E2F-1 leads to the stabilization and activation of p53, a Figure 2 Inhibition of MDM2-mediated degradation of p53 occurs through multiple mechanisms function at least partially mediated by the ability of E2F-1 to transcriptionally activate ARF expression (Figure 3 ). 82 Interestingly, several oncogenes, including Ras, Myc, v-Abl and E1A, also lead to p53-stabilization via ARF, 83 ± 86 and it is possible that deregulation of E2F-1 in response to the activation of these mitogenic oncogenes contributes to this protective response. Therefore, the overall picture emerges that ARF seems to be a central player to protect normal cells against oncogenic stimuli, through stabilization of p53 and elimination of cells that have acquired unregulated proliferative signals. An interesting picture of how complex these interconnected regulatory activities are emerged with the observation that E2F-1, which is regulated by ubiquitindependent degradation and physically interacts with MDM2, 87 ,88 also appears to be targeted for degradation by MDM2. 89 Despite the importance of the ARF/p53 pathway in mediating the apoptotic activity of E2F-1, there is evidence that E2F-1 engages additional mechanisms to prevent aberrant growth of cells. Firstly, the ability of deregulated E2F-1 to stabilize p53 is not entirely dependent on ARF expression, and in several systems oncogenic changes that lead to loss of normal control of regulation and E2F-1 activity can stabilize p53 in ARF null cells. 90, 91 Secondly, E2F-1 shows strong apoptotic activities even in the absence of p53, 92, 93 a function that appears to reflect several activities of E2F-1. E2F-1 has recently been shown to induce apoptosis in the absence of p53 by a death receptor-dependent mechanism, in which E2F-1 sensitizes cells to apoptosis in response to TNFa 94 by inhibiting anti-apoptotic responses, including activation of NF-kB (Figure 3) . A further p53 independent function of E2F-1 involves the p53 family member p73, and E2F-1 expression has recently been shown to induce transcriptional activation of p73. Since p73 shows apoptotic activities like p53, 95 increased p73 expression in response to E2F-1 is likely to mediate at least some of the p53 independent death induced by E2F-1.
The ability of p53 family proteins to influence each other is highlighted by reports that tumor-derived p53-mutants can interfere with the functions of endogenous p73 and the ability of some isoforms of p63 to function as dominant negative inhibitiors of both p63 and p53. 96, 45 Thus, it appears that the different p53 family members might influence each other's activity as well as each other's stability.
Inhibition of MDM2-mediated degradation of p53 by other mechanisms
In addition to ARF, several other proteins have been shown to stabilize p53 by inhibition of MDM2 mediated degradation, either by binding to p53 or MDM2. c-Abl binding to p53 was shown to inhibit degradation of p53 without impinging on the interaction with MDM2, 97 and stress-activated JNK has been suggested to lead to increased p53 levels by abrogating p53-interactions with MDM2. 56 Binding of RB to MDM2 has also been shown to result in the inhibition of p53 degradation without preventing the p53-MDM2 interaction, 98 and interestingly in this situation RB was shown to selectively induce the apoptotic response to p53, but not p53's transcriptional activity. b-catenin also protects p53 from ubiquitin-mediated degradation which is both MDM2-dependent and independent. 99 Regulation of sub-cellular localization is also emerging as an important mechanism to control the p53 protein stability. In a certain subset of human tumors, including neuroblastoma, p53 is sequestered in the cytoplasm and this stable p53 appears to be resistant to MDM2, probably due to a covalent modification. 100, 101 Also, stress induced p53 stabilization may result from cytoplasmic sequestration.
There is also evidence now that certain stress signals lead to transient decrease of MDM2-expression, which would allow p53-stabilization. Thus, inhibition of MDM2 mRNA-expression has been reported after treatment with several DNA damaging agents as well as after treatment of cells with kinase inhibitors that lead to stabilization of p53.
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Figure 3 The E2F-1 transcription factor activates transcription of ARF leading to elevated p53 protein, and induces degradation of Traf2 and inhibition of survival signal activation
MDM2-independent regulation of p53 and p73 stability
In addition to MDM2-regulation of p53 stability, other mechanisms to control ubiquitin dependent degradation of p53 have also been described. One of these involves the Jun-(amino)-terminal kinase (JNK), which had been shown previously to mediate the ubiquitination and degradation of other target proteins like c-Jun 104 and ATF2. 105 JNK has also been found to form associations with p53 in nonstressed cells and it has been proposed to mediate p53 ubiquitination and degradation by forming an adaptor-molecule in the E3 ubiquitin-ligase complex. 106 This JNK-mediated degradation is MDM2-independent.
Despite the similarities in their function, and the observation that, like p53, p73 protein levels are maintained by ubiquitin dependent degradation, regulation of the degradation of p53 and p73 appears to be quite distinct. This is highlighted by the response of these proteins to the oncoproteins expressed by the DNA tumor viruses, where the human papillomavirus E6 and the adenoviral proteins function to degrade p53 but not p73. 95 Clearly, stability regulation of p73 is not mediated by MDM2 binding in the same way as p53-degradation and the signals that activate p73 function are poorly understood. A recent step forward in this field came with the observation that p73 could be activated in response to DNA damage through a pathway involving the nonreceptor tyrosine kinase c-Abl. 107 ± 109 Cisplatin treatment lead to the c-Abl dependent stabilization of p73, 107 while gamma-irradiation resulted in tyrosine-phosphorylation of p73;
108,109 both of these events led to the activation of p73. Interestingly, c-Abl is itself phosphorylated by ATM, 110 ± 112 linking ATM to the DNA damage induced activation of both p53 and p73.
Conclusion
It is becoming apparent that the mechanisms regulating the p53-family of proteins are distinct, although some interesting parallels are beginning to emerge. Abnormal proliferation and deregulation of E2F-1 can activate both p53 and p73, albeit through different mechanisms, and c-Abl has also been shown to participate in the activation of p53 and p73 in response to DNA damage. The ability of p73 to respond to these kinds of signals is compatible with at least some role for p73 in protection from tumor progression, although the contribution of p73 as a tumor suppressor gene is likely to be more subtle than that seen for p53. The role for p73 and p63 during normal development 113 ± 115 suggests the possibility that signals different from those that activate p53 (which is not essential during embryogenesis) may play an important role in regulating p63 and p73 activity, and progress in this area is likely to be rapid and of great interest. 
